

Family-owned companies Recap on performance. Opportunities in Europe

Time to recap on 2022 and long-term performance

Following on our series on 'family-owned companies', as we have discussed in previous reports, we believe continued outperformance of these companies is justified on factors such as governance stability, alignment of interest between shareholders and the long-term strategy, efficient capital allocation and tighter control over management teams. In this report, we have updated performance data and the UBS family-owned list. The year 2022 saw most of asset classes delivering negative returns, and family-owned companies were no different, but they continued their outperformance against the benchmarks. The risk/reward analysis suggests timing is particularly interesting for the space, specifically in Europe, which looks cheap and where we find interesting family-owned opportunities.

Methodology that we have followed in our earlier reports

We have created six lists to showcase the family-owned companies' outperformance – three lists, both at global and European level, each representing allcaps, largecaps and small/midcaps. These lists have been benchmarked against MSCI World and MSCI Europe indices, respectively. UBS family-owned lists include c500 companies globally. We also focus the analysis on small/midcaps (<€8bn), an area where we think family-owned companies offer good opportunities among the sample size of the UBS family-owned global smallcap list at c300 companies.

Key conclusions: 'family-owned' outperformed in 2022, but not in Europe

For the last 15 years, UBS family-owned global allcaps were up by a CAGR of 11.4% vs. the MSCI World index rising by 4.5% annually, outperforming by a solid c700bps per annum. After acute underperformance in 2020, these companies have bounced back quite well in the last two years. Year-2022 performance, though, has been negative for both the global family allcaps and MSCI World, but family-controlled films have outperformed by c10%. Smallcaps' outperformance was more visible in 2022 globally (+13%); however, in Europe 'family-owned' underperformed by c6%, particulary largecaps (-10% on relative terms). We see opportunities in the space.

Interesting ideas in Europe

Stocks that we find interesting in the family-owned space in Europe and had a weak performance in the past 12 months include the likes of Bucher Industries, Schindler, Ferrovial, Porsche, Knorr Bremse, Heineken, Kone, easyJet, Ryanair, Stadler Rail and Talgo. For some of these names, we expect a good outlook ahead and see strong upside potential to our targets.

Equities

Europe including UK

Bosco Ojeda Analyst bosco.ojeda@ubs.com +34-91-436 9078

Joern Iffert, CFA Analyst joern.iffert@ubs.com +41-44-239 88 00

Guillermo Peigneux Lojo

Analyst guillermo.peigneux-lojo@ubs.com +44-20-7568 9016

> Patrick Hummel, CFA Analyst patrick.hummel@ubs.com +41-44-239 52 54

Patrick Rafaisz, CFA, FRM Analyst patrick.rafaisz@ubs.com

> +41-44-239 90 66 Sebastian Vogel, CFA

Analyst sebastian.vogel@ubs.com +41-44 239 90 45

> Sven Weier Analyst sven.weier@ubs.com +49-69-1369 8278

This report has been prepared by UBS Europe SE. **ANALYST CERTIFICATION AND REQUIRED DISCLOSURES, INCLUDING INFORMATION ON THE QUANTITATIVE RESEARCH REVIEW PUBLISHED BY UBS, BEGIN ON PAGE 10.** UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

UPDATE ON PERFORMANCE

On the following pages, we show the performance data for the UBS family-owned lists. In the past decade, we have been active on this topic, with several reports and lists of family-owned companies globally. It's interesting to see that family-owned companies have outperformed consistently in the long-term vs. global and regional indices. The rationale behind the outperformance has been discussed in more detail in the UBS research reports listed below. Factors discussed in these reports that explain the outperformance include good governance, long-term strategy allignment with shareholder ownership, focused capital allocation and tighter control over management incentives.

* Q-Series: Why do family-controlled companies outperform? April 2015

*Family-firms: Top three questions from investors (June 2015)

*Why do family-controlled companies outperform? V. 2.0 (Sept 2016)

*Are 'family-owned' firms at risk from tech disruption? (Nov 2018)

*Family-owned business and 3 themes that matter: compounders, tech disruption and megatrends (Oct. 2020).

*Thematic Research Video: Smallcaps and family-owned companies (April 2021).

Update 2022: what happened lately?

We have updated the list and below we show performance data. The charts below show how 2022 was also tough for family-owned companies in absolute terms, but overall, family companies that are included on the UBS global list outperformed global indices by c10%. The outperformance was more visible at the end of the year when global markets bounced. To some extent, there was a catch-up for quality family companies after 2020, which suffered quite a severe correction.

Figure 1: UBS Family-Owned Global Allcaps vs MSCI World - last 15 years and 2022 performance (RHS)



For the last 15 years, UBS familyowned global allcaps have returned a CAGR of 11.4%, vs the MSCI World index rising by 4.5% annually, outperforming by a solid c700bps per annum. After notable underperformance in 2020, these companies have bounced back quite well in the last two years. Year-2022 performance, though, has been negative for both the global family allcaps and MSCI World, but familycontrolled films have outperformed by c10%.

Source: UBS, Eikon Datastream

Figure 2: UBS Family-Owned Global Largecaps vs MSCI World Large - 15y and 2022 perf. (RHS)



UBS Global family-controlled largecaps showed an impressive CAGR of 13.3% for the last 15 years, while their benchmark MSCI World largecaps went up by a CAGR of 4.5%. This translates into strong outperformance of c850bps annually. The trend of outperformance continued in 2022, though at a slightly lower level with global allcaps (c6% outperformance).

Source: UBS, Eikon Datastream






UBS family-owned Global Smallcaps are up by c290% vs MSCI World Smallcaps up by c135% over the last 15 years. The outperformance was completely wiped out during the fall of 2020 Covid period, but the comeback from there has been surprisingly stronger as well. Even if we look at last-year performance, family-owned smallcaps have outperformed the global benchmark by c13%.

Source: UBS, Eikon Datastream

Figure 4: Global Risk/Return - 15-year analysis



General perception says that high rewards are normally a result of high risk. We show the risk/volatility of our family-owned lists and the benchmark, which shows that familyowned companies exhibit less volatility than non-family companies and hence are quite attractive when we consider selection on the basis of risk profile as well. The analysis is most conclusive at the global level, and in particular largecap names, as our family-owned List displays both the highest annualized returns and the lowest level of risk in the 15-year period.

Source: UBS, Eikon Datastream

Europe offers interesting opportunities

As we reflect on the charts below, the performance of European family-owned companies has been an exception, particularly for largecaps which have notably underperformed in 2022. Part of this could be related to sector exposure. Some sectors, such as banking, did well in 2022; those are a large part of European indices and few can be considered 'family-owned'. But nevertheless, Europe was already a relatively cheap market, and after the correction we see good room to screen for quality family-owned companies in the region.



Figure 5: UBS Family-Owned Europe Allcaps vs MSCI Europe - 15y and 2022 perf. (RHS) European family-owned allcaps also display the same performance against the MSCI Europe over the last 15 years, but the degree of outperformance is somewhat lower than the one observed in global family-controlled firms indices. In Europe, family-controlled allcaps rose by c270% vs the benchmark up by c130%. But 2022 saw underperformance for the European family-owned allcaps, with the benchmark falling by 12%, while the family index was down by 18% (c6% underperformance).

Source: UBS, Eikon Datastream



Figure 6: UBS Family-Owned Europe Largecaps vs MSCI Europe Largecaps - 15y and 2022 perf. (RHS)

Outperformance in the long term (15year period) suggests the same for family-owned Europe largecaps vs the Benchmark (UBS family-owned Europe largecaps up 360% vs MSCI Europe largecap up by 120%). Underperformance in 2022 has been c10% for the family-owned largecaps in Europe, which is understandable given the steep rise post the Covid crisis.

Source: UBS, Eikon Datastream




Figure 7: UBS Family-Owned Europe Smallcaps vs MSCI Europe Smallcaps - 15y and 2022 perf. (RHS)

If we look at the long term, ie, last 15 years performance (as well shortterm performance last year), we find a peculiar similarity in the movement of both the UBS family-owned Europe smallcaps and the benchmark **MSCI Europe smallcaps. Both indices** are up by the same percentage points in the last 15 years (c215%), and also behaved similarly in 2022, although the family list is slightly outperforming (c3%). This is interesting, but not very surprising, as culturally most of the smallcap companies in Europe are run by family; hence, the similarity in returns over the long term.

Source: UBS, Eikon Datastream

Figure 8: Europe Risk/Return - 15-year analysis



As we see in the risk/reward analysis, for Europe higher returns of family firms are actually coming from taking higher risks. The chart is selfexplanatory, while all the familyowned names in Europe are giving higher annualised returns over the last 15-year period, but the same is coming from higher risks as well. This particular metric differentiates from the global family-owned companies risk/reward analysis.

Source: UBS, Eikon Datastream

Figure 9: Performance table showing performance of UBS family-owned companies indices and benchmarks over different time periods

Index performance	2022	-1 Year	-3 Years	-5 Years	-10 Years	-15 Years
UBS Family Owned Global Allcaps	-9.3%	-3.3%	28.2%	23.9%	134.9%	354.7%
UBS Family Owned Global Largecaps	-13.8%	-7.8%	43.3%	56.0%	203.3%	477.5%
UBS Family Owned Global Small/Midcaps	-6.6%	-0.5%	19.8%	7.8%	100.9%	291.4%
UBS Family Owned Europe Allcaps	-18.1%	-10.7%	19.5%	10.4%	100.0%	167.5%
UBS Family Owned Europe Largecaps	-18.8%	-10.3%	29.3%	35.4%	121.2%	262.7%
UBS Family Owned Europe Small/Midcaps	-18.3%	-11.3%	13.7%	-2.9%	87.7%	120.4%
MSCI World	-19.5%	-14.0%	14.5%	25.2%	98.0%	80.5%
MSCI World Largecap	-19.3%	-14.1%	15.3%	27.3%	99.7%	78.4%
MSCI World Smallcap	-20.1%	-13.3%	11.5%	13.8%	95.6%	127.9%
MSCI Europe	-11.9%	-6.1%	8.1%	12.8%	53.7%	26.3%
MSCI Europe Largecap	-8.8%	-3.0%	9.0%	11.6%	50.1%	19.6%
MSCI Europe Smallcap	-22.5%	-15.6%	2.4%	4.4%	103.1%	113.8%

Source: UBS, Eikon Datastream, Price as on 13th January 2023

The table simply summarises the returns of the different familyowned lists (both Global and Europe) and also the performance of the **MSCI-related indices in both the** regions. One can easily see the massive outperformance of all the family-owned lists, except for the **European smallcaps family** businesses (which gave the same magnitude of returns as the relevant benchmark). As we show, familyowned companies have notably outperformed over the longer-term periods (c10 and 15 years). This also bodes well for interest in familyowned companies going forward.

Ideas in European family-owned companies

UBS covers c80 family-owned companies in Europe. Our list includes quite a few other companies that are not covered since families have very good representation in the European market. Generally speaking, Europe is well represented in family firms, well above the US market where family-ownership is more diluted, but a bit below some Asian markets (e.g. Korea, Indonesia) where families have the highest representation. European markets have been an underperformer vs. global markets in the past three years, so the region was already quite cheap, and technology and macro issues explain part of that. However, there are quite a lot of high-quality family-owned companies in Europe that are global leaders and enjoy good competitive advantages. So we see room for interesting stock-picking.

We show two tables. First, the largecaps in Europe where we have Buy ratings, interesting names with good upside potential, which have been weak performers in the past 12 months - these include Heineken, Kone, Schindler, Porsche, Barry Callebaut. The second table includes small/midcap companies with Buy ratings, interesting names with strong upside potential, which were weak performers in the past 12 months - these include Knorr Bremse, easyJet, Stadler Rail, Melia Hotels, Prosegur and Talgo.

Figure 10: Largecaps in Europe which are 'family-owned' and Buy rated by UBS


Company Name	Lead anlayst	Rating	Marketcap (€mn)	Price	Price Target	12m Perf.	P/E 2023e	EV/EBITDA 2023	Sector	Country
LVMH Moet Hennessy Louis Vuitton SA	Zuzanna Pusz, CFA	Buy	404073.88	801.90	832.00	19.2%	24.6	13.1	Clothing & Fabrics	France
L'Oréal	Guillaume Delmas	Buy	214736.04	383.60	404.00	2.0%	32.8	20.1	Cosmetics	France
Hermès International SCA	Zuzanna Pusz, CFA	Buy	174427.48	1662.00	1782.00	24.4%	43.2	25.4	Clothing & Fabrics	France
Merck KGaA	Michael Leuchten	Buy	83742.48	192.60	210.00	1.4%	19.5	13.8	Pharmaceuticals	Germany
Inditex SA	Sreedhar Mahamkali	Buy	85763.15	27.55	29.00	-1.1%	20.2	9.0	Retailers, Apparel	Spain
EssilorLuxottica	Susy Tibaldi, CFA	Buy	78007.49	175.65	210.00	2.1%	23.2	12.0	Retailers, Specialty	France
Compagnie Financiere Richemont SA	Zuzanna Pusz, CFA	Buy	80102.91	137.90	162.00	2.8%	20.1	11.7	Retailers, Specialty	Switzerland
Heineken	Nik Oliver, ACA	Buy	51609.87	89.60	105.00	-11.5%	17.8	9.6	Distillers & Brewers	Netherlands
Kuehne + Nagel	Sebastian Vogel, CFA	Buy	27599.45	226.80	246.00	-14.4%	22.4	12.2	Marine Transport	Switzerland
Sartorius AG	Michael Leuchten	Buy	25697.20	406.90	460.00	-8.7%	40.8	18.0	Healthcare Providers	Germany
SEB Group	Johan Ekblom, CFA	Buy	23896.73	123.55	146.00	0.9%	9.1	NA	Banks, Ex-S&L	Sweden
Kone	Guillermo Peigneux Lojo	Buy	26918.19	51.86	52.00	-12.6%	27.3	16.8	Industrial, Diversified	Finland
Porsche Automobil Holding SE	Patrick Hummel, CFA	Buy	16978.78	55.44	81.00	-36.9%	NA	NA	Automobile Manufacturers	Germany
Ferrovial	Bosco Ojeda	Buy	19643.40	26.78	29.00	1.7%	NA	NA	Transportation Services	Spain
Schindler	Patrick Rafaisz, CFA, FRM	Buy	21482.71	196.80	265.00	-14.4%	25.4	12.3	Industrial, Diversified	Switzerland
Exor	Patrick Hummel, CFA	Buy	17237.73	73.50	103.00	-4.9%	NA	NA	Diversified Financial	Italy
Ryanair	Jarrod Castle, CFA	Buy (CBE)	16846.37	14.84	22.50	-9.5%	11.5	7.3	Airlines	Ireland
Moncler Spa	Susy Tibaldi, CFA	Buy	14941.01	56.26	63.00	-0.5%	23.8	11.3	Clothing & Fabrics	Italy
Barry Callebaut	Joern Iffert, CFA	Buy	10601.98	1910.00	2500.00	-13.7%	24.5	13.0	Food Products	Switzerland
Sodexo	Jarrod Castle, CFA	Buy	13453.78	91.24	101.00	9.6%	15.4	7.6	Recreational Products & Services	France
Knorr-Bremse AG	Sven Weier	Buy	9485.01	58.84	74.00	-34.4%	17.1	9.2	Industrial, Diversified	Germany


Source: UBS estimates, Price as on 18th January 2023

Figure 11: Mid/Small	-caps in Europe	which are 'family-	owned' and Buy	rated by UBS
· · · · · · · · · · · · · · · · · · ·				·····

			Marketcap					EV/EBITDA		
Company Name	Lead anlayst	Rating	(€mn)	Price	Price Target	12m Perf.	P/E 2023e	2023e	Sector	Country
Wacker Chemie	Geoff Haire	Buy	6944.98	139.80	165.00	-6.3%	10.6	4.8	Chemicals, Specialty	Germany
United Internet	Polo Tang	Buy	4198.56	22.43	26.50	-34.4%	10.9	5.8	Internet Services	Germany
Bucher Industries AG	Sebastian Vogel, CFA	Buy	4288.01	419.40	422.00	<mark>-8</mark> .7%	15.7	8.0	Industrial, Diversified	Switzerland
easyJet	Jarrod Castle, CFA	Buy (CBE)	3815.56	440.30	600.00	-30.6%	23.0	3.4	Airlines	United Kingdom
JCDecaux	Richard Eary	Buy	4363.09	20.50	20.40	-7.7%	39.5	8.5	Advertising	France
Buzzi Unicem	Gregor Kuglitsch	Buy	3669.85	19.83	29.00	2.8%	8.2	2.8	Building Materials	Italy
Stadler Rail AG	Patrick Rafaisz, CFA, FRM	Buy	3709.36	36.68	43.00	-14.5%	15.6	8.5	Advanced Industrial Equipment	Switzerland
Société BIC	Kate Rusanova	Buy	2918.47	64.10	73.00	27.6%	11.0	5.6	Household Products, Non-Durable	France
Krones	Sven Weier	Buy	3380.45	107.00	121.00	18.7%	16.2	7.5	Factory Equipment	Germany
Gestamp Automoción S.A.	Juan Perez-Carrascosa	Buy	2245.66	3.90	4.00	-11.9%	8.7	4.1	Auto Parts	Spain
Motor Oil (Hellas) Corinth Refineries SA	Anna Kishmariya	Buy (CBE)	2573.67	23.40	27.00	57.0%	4.0	3.6	Oil Companies, Secondary	Greece
NOS, SGPS, S.A.	Bosco Ojeda	Buy	2053.43	3.99	4.25	17.2%	17.0	5.5	Broadcasting	Portugal
Huber+Suhner	Barbora Blaha	Buy	1768.44	89.90	115.00	14.8%	19.6	10.5	Communications Technology	Switzerland
Melia Hotels	Bosco Ojeda	Buy	1362.12	5.93	6.30	-8.2%	28.4	9.6	Lodging	Spain
Prosegur	Bosco Ojeda	Buy	1258.93	2.04	2.60	-14.3%	8.9	5.5	Industrial Services	Spain
Talgo	Bosco Ojeda	Buy	420.79	3.41	4.80	-31.5%	14.3	8.7	Industrial, Diversified	Spain

Source: UBS estimates, Price as on 18th January 2023





Here we just present the performance of our European Top-20 smallcap lists vs the MSCI Europe Smallcap index since 2006. Since inception, our top 20 list has outperformed the benchmark by c390% (CAGR of 12% for our top 20 list). For 2022, our list was down by -16%, but outperformed the benchmark by 6%, which was down by 22%. YTD 2023 is also seeing encouraging performance (top 20 up by 8.3% vs benchmark up by 7.4%).

Source: Abacus Analytics, Inc. MSCI, UBS, Note: Performance data from Inception in 29/12/2006 to June 2019 has been provided by Abacus; July 2019 onwards is UBS calculated. The indicated performance returns are based on capital appreciation, excluding dividends and transaction costs such as commissions, fees, margin interest and interest charges. Actual transactions adjusted for such transaction costs will result in reduced total returns. Prices of stocks in this performance reflect closing prices. Since its inception on 29 December 2006, the portfolio has had 520 stocks. A complete record of all the recommendations upon which the report is based is available from UBS upon written request. Past performance is not an indication of future results.

Figure 13: UBS covered family-owned names in Europe

Company Name	Lead anlayst	Rating	Marketcap (€mn)	Price	Price Target	12m Perf.	P/E 2023e	EV/EBITDA 2023e	Sector	Country
A.P. Moller-Maersk	Cristian Nedelcu, CFA	Neutral	39275.45	15245.00	10900.00	-33.5%	123.4	7.1	Marine Transport	Denmark
Anheuser-Busch InBev	Nik Oliver, ACA	Sell	94331.52	55.71	53.00	-5.8%	19.0	9.2	Distillers & Brewers	Belgium
Antofagasta Pic	Daniel Major	Sell	20281.87	1799.50	1200.00	25.1%	32.7	9.4	Mining	United Kingdo
ArcelorMittal	Andrew Jones	Sell	26092.19	28.90	26.00	-7.2%	7.6	4.2	Steel	Luxembourg
Autoaril	Louise Wiseur, CFA	Neutral	2573.92	6.70	7.10	0.5%	27.1	6.4	Recreational Products & Services	Italy
Bachem Holding AG	Barbora Blaha	Neutral	6343.16	85.05	86.00	-22.5%	51.3	32.4	Biotechnology	Switzerland
Rankinter	Ignacio Cerezo	Neutral	5803.36	6.48	7.00	24.2%	86	NA	Banks, Ex-S&L	Spain
Barry Callebaut	Joem Iffert, CFA	Buy	10601.98	1910.00	2500.00	-13.7%	24.5	13.0	Food Products	Switzerland
Bechtle AG	Kathinka de Kuyper	Neutral	4731.30	37.55	36.30	-29.2%	18.6	10.2	Software	Germany
Beiersdorf	Guillaume Delmas	Sell	25063.50	110.50	88.00	24.0%	29.3	13.7	Cosmetics	Germany
Belimo Holding AG	Sebastian Vogel, CFA	Sell	5628.51	452.50	310.00	-3.2%	40.5	27.0	Electric Components & Equipment	Switzerland
BMW	Patrick Hummel, CFA	Neutral	59600.77	91.43	70.00	-7.6%	8.3	2.6	Automobile Manufacturers	Germany
Bucher Industries AG	Sebastan Vogel, CFA	Buy	4288.01	419.40	422.00	-8.7%	15.7	8.0	Industrial. Diversified	Switzerland
Buzzi Unicem	Gregor Kuglitsch	Buy	3669.85	19.83	29.00	2.8%	8.2	2.8	Building Materials	Italy
		Neutral	8072.09	1919.00	2100.00	-27.4%	14.0	7.5	Distillers & Brewers	United Kingdo
Coloplast A/S	Graham Doyle	Neutral	24509.52	865.40	870.00	-10.8%	33.9	24.2	Advanced Medical Devices	Denmark
Compagnie Financiere Richemont SA	Zuzanna Pusz, CEA	Buy	80102.91	137.90	162.00	2.8%	20.1	11.7	Retailers, Specialty	Switzerland
Continental	David Lesne	Neutral	13240.66	66.20	67.00	-30.7%	9.2	4.7	Tires	Germany
Dassault Systèmes	Michael Briest	Neutral	47055.05	35.58	43.00	-21.6%	28.8	20.6	Software	France
DKSH Holding AG	Nicole Manion	Neutral	4992.43	75.90	75.00	2.8%	22.6	9.8	Industrial Services	Switzerland
dormakaba Holding AG	Patrick Rafaisz, CFA, FRM		1567.78	370.00	400.00	-32.4%	14.1	10.9	Advanced Industrial Equipment	Switzerland
ormakaba Holding AG Dunelm Group	Saranja Sivachelvam	Neutral	2515.74	1074.00	777.00	-32.4%	21.0	10.9	Retailers, Specialty	United Kingd
asvjet	Jarrod Castle, CFA	Buy (CBE)	3815.56	440.30	600.00	-18.9%	21.0	3.4	Airlines	United Kingd
asyJet Ebro Foods		Buy (CBE)	2458.84	440.30	600.00	-30.6%	23.0	3.4	Food Products	United Kingot Spain
Ebro Foods EssilorLuxotica	Bosco Ojeda		2458.84 78007.49	15.98	210.00	-6.0%	23.2	9.7		
	Susy Tibaldi, CFA	Buy	78007.49			-4.9%			Retailers, Specialty	France
Exor	Patrick Hummel, CFA	Buy		73.50	103.00		NA	NA	Diversified Financial Transportation Services	Italy
Ferrovial	Bosco Ojeda	Buy	19643.40	26.78	29.00	1.7%	NA 0.7	NA		Spain
Gestamp Automoción S.A.	Juan Perez-Carrascosa	Buy	2245.66	3.90	4.00	-11.9%	8.7	4.1	Auto Parts	Spain
1 & M	Sreedhar Mahamkali	Neutral	19126.36	128.84	119.00	-25.8%	22.7	7.4	Retailers, Apparel	Sweden
Heineken	Nik Oliver, ACA	Buy	51609.87	89.60	105.00	-11.5%	17.8	9.6	Distillers & Brewers	Netherlands
ienkel	Guillaume Delmas	Neutral	27621.51	66.82	62.00	-15.9%	16.4	9.0	Household Products, Non-Durable	Germany
Hermès International SCA	Zuzanna Pusz, CFA	Buy	174427.48	1662.00	1782.00	24.4%	43.2	25.4	Clothing & Fabrics	France
Hexagon AB	Magnus Kruber, CFA	Neutral	27482.53	119.30	114.50	-5.8%	22.2	13.5	Factory Equipment	Sweden
luber+Suhner	Barbora Blaha	Buy	1768.44	89.90	115.00	14.8%	19.6	10.5	Communications Technology	Switzerland
nditex SA	Sreedhar Mahamkali	Buy	85763.15	27.55	29.00	-1.1%	20.2	9.0	Retailers, Apparel	Spain
psen SA	Michael Leuchten	Neutral	8783.76	104.80	108.00	26.1%	13.3	7.7	Biotechnology	France
srael Chemicals Limited	Geoff Haire	Neutral	9733.50	27.70	29.00	-17.1%	9.0	5.3	Chemicals, Specialty	Israel
JCDecaux	Richard Eary	Buy	4363.09	20.50	20.40	-7.7%	39.5	8.5	Advertising	France
Jeronimo Martins	Michal Potyra, CFA	Neutral	12837.52	20.40	22.00	-4.8%	18.2	7.0	Food Retailers & Wholesalers	Portugal
Kering	Zuzanna Pusz, CFA	Neutral	67736.60	543.70	540.00	-18.6%	17.8	9.8	Clothing & Fabrics	France
Knorr-Bremse AG	Sven Weier	Buy	9485.01	58.84	74.00	-34.4%	17.1	9.2	Industrial, Diversified	Germany
Kone	Guillermo Peigneux Lojo	Buy	26918.19	51.86	52.00	-12.6%	27.3	16.8	Industrial, Diversified	Finland
Krones	Sven Weier	Buy	3380.45	107.00	121.00	18.7%	16.2	7.5	Factory Equipment	Germany
Kudelski	Joern Iffert, CFA	Sell	137.65	2.51	2.00	-27.9%	46.8	5.8	Software	Switzerland
Kuehne + Nagel	Sebastian Vogel, CFA	Buy	27599.45	226.80	246.00	-14.4%	22.4	12.2	Marine Transport	Switzerland
L'Oréal	Guillaume Delmas	Buy	214736.04	383.60	404.00	2.0%	32.8	20.1	Cosmetics	France
LVMH Moet Hennessy Louis Vuitton SA	Zuzanna Pusz, CFA	Buy	404073.88	801.90	832.00	19.2%	24.6	13.1	Clothing & Fabrics	France
Mediaforeurope NV	Richard Eary	Neutral (CBE)	1150.40	0.61	0.62	-51.9%	7.1	8.3	Broadcasting	Italy
Melia Hotels	Bosco Ojeda	Buy	1362.12	5.93	6.30	-8.2%	28.4	9.6	Lodging	Spain
Merck KGaA	Michael Leuchten	Buy	83742.48	192.60	210.00	1.4%	19.5	13.8	Pharmaceuticals	Germany
Moncler Spa	Susy Tibaldi, CFA	Buy	14941.01	56.26	63.00	-0.5%	23.8	11.3	Clothing & Fabrics	Italy
Motor Oil (Hellas) Corinth Refineries SA	Anna Kishmariya	Buy (CBE)	2573.67	23.40	27.00	57.0%	4.0	3.6	Oil Companies, Secondary	Greece
NOS, SGPS, S.A.	Bosco Ojeda	Buy	2053.43	3.99	4.25	17.2%	17.0	5.5	Broadcasting	Portugal
Drkla	Kate Rusanova	Sell	6777.85	72.88	65.00	-16.2%	13.8	7.4	Food Products	Norway
Phoenix Mecano	Joern Iffert, CFA	Sell	333.63	344.00	330.00	-17.4%	12.5	6.0	Electric Components & Equipment	Switzerland
Plastic Omnium	Juan Perez-Carrascosa	Sell	2353.29	15.84	13.00	-31.4%	9.1	3.7	Auto Parts	France
Porsche Automobil Holding SE	Patrick Hummel, CFA	Buy	16978.78	55.44	81.00	-36.9%	NA	NA	Automobile Manufacturers	Germany
Prosegur	Bosco Ojeda	Buy	1258.93	2.04	2.60	-14.3%	8.9	5.5	Industrial Services	Spain
Randstad Holding NV	Rory McKenzie	Sell	11028.96	59.94	40.00	-1.4%	20.5	11.0	Industrial Services	Netherlands
Renishaw	Rory Smith	Sel	3222.10	3872.00	3000.00	-16.6%	25.2	13.7	Electric Components & Equipment	United Kingdo
Roche	Michael Leuchten	Neutral	249104.86	295.90	315.00	-18.9%	15.2	10.5	Pharmaceuticals	Switzerland
Ryanair	Jarrod Castle, CFA	Buy (CBE)	16846.37	14.84	22.50	-9.5%	11.5	7.3	Airlines	Ireland
Salvatore Ferragamo SPA	Susy Tibaldi CFA	Sell	3048.68	18.25	14.00	-9.576	85.2	7.5	Clothing & Eabrics	Italy
Sartorius AG	Michael Leuchten	Buy	25697.20	406.90	460.00	-8.7%	40.8	18.0	Healthcare Providers	Germany
Schaeffer	Juan Perez-Carrascosa	Neutral	4355.64	6.54	460.00	-0.7%	9.1	4.3	Auto Parts	Germany
Schaetter	Patrick Rafaisz, CFA, FRM		21482.71	0.54	265.00	-11.0%	25.4	4.3	Industrial, Diversified	Switzerland
SEB Group	Johan Ekblom, CFA	Buy	23896.73	196.80	146.00	-14.4%	9.1	12.3 NA	Banks, Ex-S&L	
SEB Group SFS Group AG				99.10	97.00	-26.6%	9.1			Sweden Switzerland
SFS Group AG Sika	Joem Iffert, CFA	Neutral	3918.50	99.10 262.00	97.00 240.00	-26.6%		8.7	Industrial, Diversified	
	Patrick Rafaisz, CFA, FRM		40172.36				32.6	21.1	Building Materials	Switzerland
Société BIC	Kate Rusanova	Buy	2918.47	64.10	73.00	27.6%	11.0	5.6	Household Products, Non-Durable	France
Sodexo	Jarrod Castle, CFA	Buy	13453.78	91.24	101.00	9.6%	15.4	7.6	Recreational Products & Services	France
Solaria	Bosco Ojeda	Neutral (CBE)	2470.26	19.77	18.20	27.1%	32.2	18.8	Electric Utilities	Spain
Solvay	Geoff Haire	Sell	10786.27	104.00	83.00	-3.3%	12.1	7.2	Chemicals, Commodity	Belgium
Stadler Rail AG	Patrick Rafaisz, CFA, FRM		3709.36	36.68	43.00	-14.5%	15.6	8.5	Advanced Industrial Equipment	Switzerland
Straumann	Graham Doyle	Sell	19898.55	123.70	96.00	-21.1%	40.0	27.0	Medical Supplies	Switzerland
Swatch Group AG	Zuzanna Pusz, CFA	Neutral	15379.76	304.40	287.00	5.1%	16.0	7.8	Retailers, Specialty	Switzerland
Talgo	Bosco Ojeda	Buy	420.79	3.41	4.80	-31.5%	14.3	8.7	Industrial, Diversified	Spain
Tod's	Susy Tibaldi, CFA	Neutral (CBE)	1060.98	32.06	34.00	-28.1%	26.8	7.0	Clothing & Fabrics	Italy
United Internet	Polo Tang	Buy	4198.56	22.43	26.50	-34.4%	10.9	5.8	Internet Services	Germany
Viscofan	Bosco Ojeda	Neutral	2786.68	59.80	65.70	15.1%	18.2	9.9	Food Products	Spain
/olkswapen	Patrick Hummel, CFA	Neutral	73328.54	125.20	130.00	-34.3%	8.1	1.7	Automobile Manufacturers	Germany

Source: UBS estimates, Price as on 18th January 2023

We would like to thank **Rajiv Daga**, our research support service professionals, for their assistance in preparing this research report.

Valuation Method and Risk Statement

There are risks in investing in equities and smallcaps may entail high specific risks linked to external factors such as the macro performance, financial risk, country risk and specific stock risks that could be subject to uncertain returns.

The risks of investing in European family-owned companies include specific risks relating to each company as well as generic risks such as macroeconomic impact, sovereign risk in the European union, exposure to emerging markets, financial risk, etc. On top of that, family-owned companies can face risks related to large shareholder treatment of minority shareholders, liquidity risks, and risks related to conflicts of interests.

The stocks mentioned are affected by the overall state of the economy in various ways, some directly, by levels of interest rates, inflation, oil price levels, and some indirectly, by disposable income growth, consumer confidence etc. In addition, there are company-specific risks for any investment in smallcaps, which can be material.

Required Disclosures

This report has been prepared by UBS Europe SE, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; certain additional disclosures concerning UBS research recommendations; and terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 20 January 2023 03:55 PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. Quantitative Research Review: UBS publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please see the Quantitative Research Review Addendum at the back of this report, where applicable. For previous responses please make reference to (i) previous UBS research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at https://neo.ubs.com/quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research Team on ga@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research team on the email above.

Analyst Certification:

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is $> 6\%$ above the MRA.	55%	24%
Neutral	FSR is between -6% and 6% of the MRA.	36%	21%
Sell	FSR is > 6% below the MRA.	9%	18%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

UBS Investment Research: Global Equity Rating Definitions

Source: UBS. Rating allocations are as of 31 December 2022.

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4: Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. In some cases, this yield may be based on accrued dividends. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount: **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/ qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS AG: Joern Iffert, CFA, Patrick Hummel, CFA, Patrick Rafaisz, CFA, FRM, Sebastian Vogel, CFA.**UBS Europe SE:** Bosco Ojeda, Guillermo Peigneux Lojo, Sven Weier.

Company Disclosures

Company Name	Reuters	12-month rating	Price	Price date
Barry Callebaut ^{13,59,5,7}	BARN.S	Buy	CHF1,920	19 Jan 2023
Bucher Industries AG ^{5,7}	BUCN.S	Buy	CHF408.80	19 Jan 2023
Ferrovial	FER.MC	Buy	€26.39	19 Jan 2023
Heineken ¹²	HEIN.AS	Buy	€90.84	19 Jan 2023
Knorr-Bremse AG	KBX.DE	Buy	€57.04	19 Jan 2023
Kone	KNEBV.HE	Buy	€51.04	19 Jan 2023
Melia Hotels ⁴	MEL.MC	Buy	€5.90	19 Jan 2023
Porsche Automobil Holding SE ²	PSHG_p.DE	Buy	€54.26	19 Jan 2023
Prosegur	PSG.MC	Buy	€1.99	19 Jan 2023
Ryanair ^{16,20}	RYA.I	Buy (CBE)	€14.86	19 Jan 2023
Schindler ⁵	SCHP.S	Buy	CHF192.55	19 Jan 2023
Stadler Rail AG ^{5,7}	SRAIL.S	Buy	CHF35.56	19 Jan 2023
Talgo	TLGO.MC	Buy	€3.38	19 Jan 2023
easyJet ²⁰	EZJ.L	Buy (CBE)	436p	19 Jan 2023

Source: UBS. All prices as of local market close. Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date.

2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.

4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.

5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.

7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.

12. An employee of UBS AG, its affiliates or subsidiaries is an officer, director, or advisory board member of this company.

13. UBS Group AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company's common equity securities as of last month's end (or the prior month's end if this report is dated less than 10 days after the most recent month's end).

16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

20. Because this security exhibits higher-than-average volatility, the FSR has been set at 25% above the MRA for a Buy rating, and at -25% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).

59. UBS Fund Management (Switzerland) AG beneficially owns more than 3 of the total issued share capital of this company.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Additional Prices: DKSH Holding AG, CHF75.15 (19 Jan 2023); Salvatore Ferragamo SPA, €17.85 (19 Jan 2023); Coca-Cola Hellenic Bottling Company S.A, 1929p (19 Jan 2023); Moncler Spa, €55.02 (19 Jan 2023); Gestamp Automoción S.A., €3.74 (19 Jan 2023); Kudelski, CHF2.52 (19 Jan 2023); Antofagasta Plc, 1723p (19 Jan 2023); ArcelorMittal, €27.90 (19 Jan 2023); Continental, €62.60 (19 Jan 2023); EssilorLuxottica, €170.95 (19 Jan 2023); LVMH Moet Hennessy Louis Vuitton SA, €776.60 (19 Jan 2023); Coloplast A/S, DKr851.20 (19 Jan 2023); L'Oréal, €376.60 (19 Jan 2023); JCDecaux, €20.58 (19 Jan 2023); Bechtle AG, €36.06 (19 Jan 2023); Kering, €530.00 (19 Jan 2023); Krones, €105.00 (19 Jan 2023); Schaeffler, €6.28 (19 Jan 2023); A.P. Moller-Maersk, DKr14680.00 (19 Jan 2023); United Internet, €21.96 (19 Jan 2023); Société BIC, €63.35 (19 Jan 2023); Dassault Systèmes, €34.84 (19 Jan 2023); Sodexo, €90.64 (19 Jan 2023); Hermès International SCA, €1614.50 (19 Jan 2023); Huber+Suhner, CHF89.30 (19 Jan 2023); NOS, SGPS, S.A., €3.97 (19 Jan 2023); Sika, CHF256.30 (19 Jan 2023); Autogrill, €6.60 (19 Jan 2023); Bachem Holding AG, CHF82.30 (19 Jan 2023); Jeronimo Martins, €19.84 (19 Jan 2023); BMW, €90.02 (19 Jan 2023); Compagnie Financiere Richemont SA, CHF135.05 (19 Jan 2023); Solvay, €102.50 (19 Jan 2023); Phoenix Mecano, CHF344.00 (19 Jan 2023); Buzzi Unicem, €19.68 (19 Jan 2023); Kuehne + Nagel, CHF217.10 (19 Jan 2023); Anheuser-Busch InBev, €55.05 (19 Jan 2023); Viscofan, €58.95 (19 Jan 2023); Ipsen SA, €103.50 (19 Jan 2023); Bankinter, €6.29 (19 Jan 2023); Dunelm Group, 1042p (19 Jan 2023); Roche, CHF294.45 (19 Jan 2023); Straumann, CHF120.60 (19 Jan 2023); dormakaba Holding AG, CHF367.50 (19 Jan 2023); Orkla, NKr72.88 (19 Jan 2023); Mediaforeurope NV, €0.59 (19 Jan 2023); Hexagon AB, SKr116.20 (19 Jan 2023); SEB Group, SKr123.55 (19 Jan 2023); Tod's, €31.72 (19 Jan 2023); Volkswagen, €123.14 (19 Jan 2023); Ebro Foods, €15.90 (19 Jan 2023); SFS Group AG, CHF98.00 (19 Jan 2023); Renishaw, 3848p (19 Jan 2023); Beiersdorf, €111.15 (19 Jan 2023); Randstad Holding NV, €59.10 (19 Jan 2023); Inditex SA, €26.90 (19 Jan 2023); Sartorius AG, €396.80 (19 Jan 2023); Motor Oil (Hellas) Corinth Refineries SA, €22.16 (19 Jan 2023); Israel Chemicals Limited, NIS27.22 (19 Jan 2023); Belimo Holding AG, CHF464.00 (19 Jan 2023); Swatch Group AG, CHF296.60 (19 Jan 2023); Wacker Chemie, €135.10 (19 Jan 2023); Merck KGaA, €189.00 (19 Jan 2023); Exor, €71.46 (19 Jan 2023); H & M, SKr125.34 (19 Jan 2023); Henkel, €66.14 (19 Jan 2023); Solaria, €19.27 (19 Jan 2023); Plastic Omnium, €15.06 (19 Jan 2023); Source: UBS. All prices as of local market close.

The Disclaimer relevant to Global Wealth Management clients follows the Global Disclaimer.

Global Disclaimer

This document has been prepared by UBS Europe SE, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. This document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the document.

Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo. Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab and you would like to access that data please contact your UBS sales representative. UBS Evidence Lab data is available on UBS Neo. The level and types of services provided by Global Research and UBS Evidence Lab to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and ivestment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a system, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (<u>https://www.ubs.com/global/en/investment-bank/regulatory.html</u>) and to UBS's Terms of Use/Disclaimer (<u>https://www.ubs.com/global/en/investment-bank/regulatory.html</u>) and to UBS's in accordance with our Privacy Statement (<u>https://www.ubs.com/global/en/legalinfo2/privacy.html</u>) and cookies in accordance with our Privacy Statement (<u>https://www.ubs.com/global/en/legalinfo2/privacy.html</u>) and cookie notice (<u>https://www.ubs.com/glob</u>

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

In certain circumstances (including for example, if you are an academic or a member of the media) you may receive Global Research otherwise than in the capacity of a client of UBS and you understand and agree that (i) the Global Research is provided to you for information purposes only; (ii) for the purposes of receiving it you are not intended to be and will not be treated as a "client" of UBS for any legal or regulatory purpose; (iii) the Global Research must not be relied on or acted upon for any purpose; and (iv) such content is subject to the relevant disclaimers that follow.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. The recipient should carefully read this document in its entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <u>https://www.theocc.com/publications/risks/riskchap1.jsp</u> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

(i) valuation or accounting purposes;

(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or

(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit https://www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas

within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe**: Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin) Rules and according to MIFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the BaFin and the ECB. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Where an analyst of UBS AG courpe SE and UBS AG. contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. In all cases it is distributed by UBS London Branch. **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to any other offering and capital market Roard. However, according to the public of Turkey without the prior approval of the Capital Market Board. However, according to any other offering and capital market Roard by the Roard to the polytic abroad by the Roard to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). Should not be construed as an individual Investment Recommendation for the purpose of the Russian Law - Federal Law #39-FZ ON THE SECURITIES MARKET Articles 6.1-6.2. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). Italy: Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. France: Prepared by UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch. Second by UBS Europe SE, Italy Branch. Second Branch. Second Branch and Second Branch and Second Branch. Second Branch and Second Branch and Second Branch and Branch and Second Branch. Second Branch and Second Branch and Second Branch and Branch an prepared by DBS Europe SE, Sweden Branch As contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. Sweden Branch As contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. Sweden Branch As contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. Sweden Branch Services Provider (FSP 7328). Saudi Arabia: This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS (Saudi Arabia; Caribia Distributed by the Caribia Distributed and the Vision of Saudi Arabia; UBC (Saudi Arabia; Caribia Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai**: The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, no is it licensed by the UAE securities and Commodities Authority. Israel: This Material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have an Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this Material must not be furnished to, relied on or acted upon by any other persons. **United States**: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a **'non-US affiliate'**) to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc., accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registrations. **Brazil** Caretora de Câmbio. Titulos exercites securities mentioned hu IBS Regail. investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil**: Except as otherwise specified herein, this Material is prepared by UBS Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A.¹ (UBS Brasil COTVM) to persons who are eligible investors residing in Brazil, which are considered to be Professional Investors (Investidores Profissionais), as designated by the applicable regulation, mainly the CVM Resolution No. 30 from the 11th of May 2021 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). ¹UBS CCTVM is a subsidiary of UBS BB Servicos de Assessoria Financeira e Participacoes S.A. ("UBS BB"). UBS BB is an association between UBS AG and Banco do Brasil (through its subsidiary BB – Banco de Investimentos S.A.), of which UBS AG is the majority owner and which provides investment banking services and coverage in Brazil, Argentina, Paraguay, Peru and Uruguay. **Hong Kong:** Distributed by UBS Securities Asia Limited. Please contact local licensed persons of UBS Securities Asia Limited in respect of any matters arising from, or in connection with, the analysis or document **Singapore:** Distributed by UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch. Please contact local adviser under the Singapore Branch and a wholesale bank licensed under the Singapore Branch, an exempt financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch. Are exempt financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch. Please contact Securities arising from, or in connection with, the analysis or document **Singapore** financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial Advisers Act (Cap. 110) and a financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). Japan: Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this report has been prepared by UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the report. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 G13 and holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS AG (ABN 47 088 129 G08 586 481 and holder of Australian Financial Services License No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation on needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives financial arguistion, or potential arguistion of a particular objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. **New Zealand:** Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India**: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number UG7120MH196PTC097299) *2/*F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INX000010809. UBS AG, its affiliates or subsidiaries may have tencil in the subject Indian company/companies. UBS AG, its affiliates or subsidiaries may have financial interests (e.g. loan/derivative products, rights to or interests in investments, etc.) in the subject Indian company / companies from time to time. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have financial interests (e.g. loan/derivative products, rights to or interests in investments per to investment banking securities-related services and/or non-securities related services and/or non-securities during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services. With regard to information on associates, please refer to the Annual Report at: https://www.ubs.com/global/en/about ubs/investor relations/ instributed by UBS Securities Pte. LTD. Taipei Branch, which is licensed and regulated by Taiwan. Information and material on securities/ instruments that are traded in a Taiwan organized exchange is deemed to be issued and distributed by UBS Securities Pte. LTD. Taipei Branch, which is licensed and usel and regulated by Taiwan. Information and material ons on the covered companies or any companies or any companies or any companies or any companies report to the Annual Report at: <a href="https://www.ubs.com/global/en/abo

English law. UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Global Wealth Management Disclaimer

You receive this document in your capacity as a client of UBS Global Wealth Management. This publication has been distributed to you by UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates (**"UBS"**) with whom you have a banking relationship with. The full name of the distributing affiliate and its competent authority can be found in the country-specific disclaimer at the end of this document.

The date and time of the first dissemination of this publication is the same as the date and time of its publication.

Risk information:

You agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research, and that you shall not extract data from any research or estimates, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is **for your information only**; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the information (as defined below).

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes: (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument financial contract; or (iii) to measure the performance of any financial instrument fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS (including between Global Wealth Management and UBS Global Research) and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit https://www.ubs.com/research-methodology.

Research will initiate, update and cease coverage solely at the discretion of research management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Options and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "Characteristics and Risks of Standardized Options". You may read the document at https://www.theocc.com/about/publications/character-risks.jpp or ask your financial advisor for a copy.

Investing in structured investments involves significant risks. For a detailed discussion of the risks involved in investing in any particular structured investment, you must read the relevant offering materials for that investment. Structured investments are unsecured obligations of a particular issuer with returns linked to the performance of an underlying asset. Depending on the terms of the investment, investors could lose all or a substantial portion of their investment based on the performance of the underlying asset. Investors could also lose their entire investment if the issuer becomes insolvent. UBS does not guarantee in any way the obligations or the financial information provided by any issuer. Structured investments are not traditional investing and investing in a structured investment is not equivalent to investing directly in the underlying asset. Structured investments may have limited or no liquidity, and investors should be prepared to hold their investment to maturity. The return of structured investments may be limited by a maximum gain, participation rate or other feature. Structured investments with similar terms. Structured investments include costs and fees which are generally embedded in the price of the investment. The tax treatment of a structured investment may be complex and may differ from a direct investment in the underlying asset. UBS and its employees do not provide tax advice. Investors should consult their own tax advisor about their own tax situation before investing in any securities.

Important Information About Sustainable Investing Strategies: Sustainable investing strategies aim to consider and incorporate environmental, social and governance (ESG) factors into investment process and portfolio construction. Strategies across geographies and styles approach ESG analysis and incorporate the findings in a variety of ways. Incorporating ESG factors or Sustainable Investment objective and other principal investment strategies. The returns on a portfolio consisting primarily of sustainable investment objective and other principal investment strategies. The returns on a portfolio considered by the portfolio manager, and the investment opportunities available to such portfolios may differ. Companies may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility, sustainability, and/or impact performance.

Within the past 12 months UBS Switzerland AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

If you require detailed information on disclosures of interest or conflict of interest as required by Market Abuse Regulation please contact the mailbox <u>MAR disclosures twopager@ubs.com</u>. Please note that e-mail communication is unsecured.

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

Bahrain: UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain to undertake banking or investment business activities in Bahrain. Therefore, prospects/clients do not have any protection under local banking and investment services laws and regulations. Brazil: This report is only intended for Brazilian residents who are directly purchasing or selling securities in the Brazil capital market through a local authorized institution. Canada: The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. In Canada, this publication is distributed by UBS Investment Management Canada Inc. China: This report and any offering material such as term sheet, research report, other product or service documentation or any other information (the "Material") sent with this report was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly delete it and inform UBS immediately. This report is prepared by UBS Switzerland AG or its offshore subsidiary or affiliate (collectively as "UBS Offshore"). UBS Offshore is an entity incorporated out of China and is not licensed, supervised or regulated in China to carry out banking or securities business. The recipient should not contact the analysts or UBS Offshore which produced this report for advice as they are not licensed to provide securities investment advice in China. UBS Investment Bank (including Research) has its own wholly independent research and views which at times may vary from the views of UBS Global Wealth Management. The recipient should not use this document or otherwise rely on any of the information contained in this report in making investment decisions and UBS takes no responsibility in this regard. Czech Republic: UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment services in the Czech Republic. This communication and/or material is distributed for marketing purposes and constitutes a "Commercial Message" under the laws of Czech Republic in relation to banking and/or investment services. Please notify UBS if you do not wish to receive any further correspondence. **Denmark**: This publication is not intended to constitute a public offer under Danish law. It is distributed only for information purposes to clients of UBS Europe SE, Denmark Branch, filial af UBS Europe SE, Denmark, registered with the Danish Commerce and Companies Agency, under No. 38 17 24 33. UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the European Central Bank, the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin"), as well as of the Danish Financial Supervisory Authority (Finanstilsynet), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by BaFin. Egypt: Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have not been and will not be registered with the Egyptian Financial Regulatory Authority (FRA). France: This publication is not intended to constitute a public offer under French law, it does not constitute a personal recommendation as it is distributed only for information purposes to clients of UBS (France) S.A., French "société anonyme" with share capital of \in 132.975.556, at 69 boulevard Haussmann F-75008 Paris, registered with the "Registre du Commerce et des Sociétés" of Paris under N° B 421 255 670. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code monétaire et financier", regulated by French banking and financial authorities as the "Autorité de contrôle prudentiel et de résolution" and "Autorité des marchés financiers", to which this publication has not been submitted for approval. Germany: This publication is not intended to constitute a public offer under German law. It is distributed only for information purposes to clients of UBS Europe SE, Germany, with place of business at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UB Sturope SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin") and supervised jointly by the Europeae. Central Bank, the German Central Bank (Deutsche Bundesbank) and BaFin, to which this publication has not been submitted for approval. **Hong Kong SAR**: This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. UBS AG Hong Kong Branch is incorporated in Switzerland with limited liability. India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. UBS AG, its affiliates or subsidiaries may have financial interests (e.g. like loan/derivative products, rights to or interests in investments, etc.) in the subject Indian company/companies from time to time. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/ companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: <u>https://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html</u>. **Indonesia**: This communication and any offering material term sheet, research report, other product or service documentation or any other information (the "Material") sent with this communication was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the Material erroneously, UBS asks that you kindly delete the e-mail and inform UBS immediately. The Material, where provided, was provided for your information only and is not to be further distributed without the consent of UBS. None of the Material has been registered or filed under the prevailing laws and with any financial or regulatory authority in your jurisdiction. The Material may not have been approved, disapproved, endorsed, registered or filed with any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or products or futures contracts). The Material is neither an offer nor a solicitation to

enter into any transaction or contract (including futures contracts) nor is it an offer to buy or to sell any securities or products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Any and all advice provided on and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. Israel: UBS is a premier global financial firm offering wealth management, asset management and investment banking services from its headquarters in Switzerland and its operations in over 50 countries worldwide to individual, corporate and institutional investors. In Israel, UBS Switzerland AG is registered as Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd., a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd. is an Investment Marketing licensee which engages in Investment Marketing and is regulated by the Israel Securities Authority. This publication is intended for information only and is not intended as an offer to buy or solicitation of an offer. Furthermore, this publication is not intended as an investment advice. No action has been, or will be, taken in Israel that would permit an offering of the product(s) mentioned in this document or a distribution of this document to the public in Israel. In particular, this document has not been reviewed or approved by the Israeli Securities Authority. The product(s) mentioned in this document is/are being offered to a limited number of sophisticated investors who qualify as one of the investors listed in the first supplement to the Israeli Securities Law, 5728-1968. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Anyone who purchases the product(s) mentioned herein shall do so for its own benefit and for its own account and not with the aim or intention of distributing or offering the product(s) to other parties. Anyone who purchases the product(s) shall do so in accordance with its own understanding and discretion and after it has received any relevant financial, legal, business, tax or other advice or opinion required by it in connection with such purchase(s). The word "advice" and/or any of its equivalent terms shall be read and construed in conjunction with the definition of the term "investment marketing" as defined under the Israeli Regulation of Investment Advice, Investment Marketing and Portfolio Management Law. The Swiss laws and regulations require a number of mandatory disclosures to be made in independent financial research reports or recommendations. Pursuant to the Swiss Financial Market Infrastructure Act and the Financial Market Infrastructure Ordinance-FINMA, banks must disclose the percentage of voting rights they hold in companies being researched, if these holdings are equal to or exceed the statutory thresholds. In addition, the Directives on the Independence of Financial Research, issued by the Swiss Bankers Association, mandate a number of disclosures, including the disclosure of potential conflicts of interest, the participation within previous 12 months in any securities issues on behalf of the company being researched, as well as the fact that remuneration paid to the financial analysts is based generally upon the performance of (i) the new issues department or investment banking; or (ii) securities trading performance (including proprietary trading) or sales. **Italy**: This publication is not intended to constitute a public offer under Italian law. It is distributed only for information purposes to clients of UBS Europe SE, Succursale Italia, with place of business at Via del Vecchio Politecnico, 3-20121 Milano. UBS Europe SE, Succursale Italia is subject to the joint supervision of the European Central Bank, the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Succursale Italia is subject to the joint supervision of the European Central bank, the German Central bank (Dedistre Bundesbank), the German Pedra manual Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin"), as well as of the Bank of Italy (Banca d'Italia) and the Italian Financial Markets Supervisory Authority (CONSOB - Commissione Nazionale per le Società e la Borsa), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by BaFin. Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place of business is 1, IFC Jersey, St Helier, Jersey, JE2 3BX. Luxembourg Entropy of a set and balance of base and balance of bas supervised by the Luxembourg prudential supervisory authority (Commission de Surveillance du Secteur Financier), in its role as host member state authority. This publication has not been submitted for approval to any public supervisory authority. **Malaysia**: This communication and any offering material term sheet, research report, other product or service documentation or any other information (the "Material") sent with this communication was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the Material erroneously, UBS asks that you kindly delete the e-mail and inform UBS immediately. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved, endorsed, registered or filed with any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or derivatives products). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or derivatives products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Any and all advice provided on and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. Mexico: This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland AG, incorporated as a non-independent investment advisor under the Mexican regulation due to the relation with a Foreign Bank. UBS Asesores is registered under number 30060-001-(14115)-21/06/2016 and subject to the supervision of the Mexican Banking and Securities Commission ("CNBV") exclusively regarding the rendering of (i) portfolio management services, (ii) securities investment advisory services, analysis and issuance of individual investment recommendations, and (iii) anti-money laundering and terrorism financing matters. This UBS publication or any material related thereto is addressed only to Sophisticated or Institutional Investors located in Mexico. Research reports only reflect the views of the analysts responsible for the report. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to which such analyst(s) render(s) services. **Nigeria**: The investment products mentioned in this material are not being offered or sold by UBS to the public in Nigeria and they have not been submitted for approval nor registered with the Securities and Exchange Commission of Nigeria. If you are interested in products of this nature, please let us know. The investment products mentioned in this material are not being directed to, and are not being made available for subscription by any persons within Nigeria other than the selected investors to whom the offer materials have been addressed as a private sale or domestic concern within the exemption and meaning of Section 69(2) of the Investments and Securities Act, 2007 (ISA). This material has been provided to you at your specific unsolicited request and for your information only. **Philippines:** This communication was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the Material erroneously, UBS asks that you kindly delete the e-mail and inform UBS immediately. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved, endorsed, registered or filed with any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or derivatives products). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or derivatives produces. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Any and all advice provided on and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. Portugal: UBS Switzerland AG is not licensed to conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the portuguese regulators (Bank of Portugal "Banco de Portugal" and Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). Qatar: UBS Qatar LLC is authorized by the Qatar Financial Centre Regulatory Authority, with QFC no. 01169, and has its registered office at 14th Floor, Burj Alfardan Tower, Building 157, Street No. 301, Area No. 69, Al Majdami, Lusail, Qatar. UBS Qatar LLC neither offers any brokerage services nor executes any order with, for or on behalf of its clients. A client order will have to be placed with, and executed by, UBS Switzerland AG in Switzerland or an affiliate of UBS Switzerland AG, that is domiciled outside Qatar. It is in the sole discretion of UBS Switzerland AG in Switzerland or its affiliate to accept or reject an order and UBS Qatar LLC does not have authority to provide a confirmation in this respect. UBS Qatar LLC may however communicate payment orders and investment instructions to UBS Switzerland AG in Switzerland for receipt, acceptance and execution. UBS Qatar LLC is not authorized to act for and on behalf of UBS Switzerland AG or an affiliate of UBS Switzerland AG. This document and any attachments hereto are intended for eligible counterparties and business customers only. Russia: This document or information contained therein is for information purposes only and constitutes neither a public nor a private offering, is not an invitation to make offers, to sell, exchange or otherwise transfer any financial instruments in the Russian Federation to or for the benefit of any Russian person or entity and does not constitute an advertisement or offering of securities in the Russian Federation within the meaning of Russian securities laws. The information contained herein is not an "individual investment recommendation" as defined in Federal Law of 22 April 1996 No 39-FZ "On Securities Market" (as amended) and the financial instruments and operations specified herein may not be suitable for your investment profile or your investment goals or expectations. The determination of whether or not such financial instruments and operations are in your interests or are suitable for your investment goals, investment horizon or the acceptable risk level is your responsibility. We assume no liability for any losses connected with making any such operations or investing into any such financial instruments and we do not recommend to use such information as the only source of information for making an investment decision. Saudi Arabia: UBS Saudi Arabia is authorised and regulated by the Capital Market Authority to conduct securities business under licence number 08113-37. Singapore: Clients of UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. UBS AG is incorporated in Switzerland with limited liability. UBS AG has a branch registered in Singapore (UEN S98FC5560C). This communication and any offering material term sheet, research report, other product or service documentation or any other

information (the "Material") sent with this communication was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the Material erroneously, UBS asks that you kindly delete the e-mail and inform UBS immediately. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or products or futures contracts). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Any and all advice provided on and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. Sweden: This publication is not intended to constitute a public offer under Swedish law. It is distributed only for information purposes to clients of UBS Europe SE, Sweden Bankfilial, with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden, registered with the Swedish Companies Registration Office under Reg. No Sweden Bankinia, with place of business at Regeningsgatan 38, 11-35 stocknown, registered with the Swedish Companies Registration Once under Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the European Central Bank, the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin"), as well as of the Swedish supervisory authority (Finansinspektionen), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by BaFin. **Taiwan**: This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. Thailand: This communication and any offering material, term sheet, research report, other product or service documentation or any other information (the "Material") sent with this communication were done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the Material erroneously, UBS asks that you kindly delete the e-mail and inform UBS immediately. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved, endorsed, registered or filed with any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or derivatives products). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or derivatives products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Any and all advice provided and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. Turkey: The information in this document is not provided for the purpose of offering, marketing or sale of any capital market instrument or service in the Republic of Turkey. Therefore, this document may not be considered as an offer made, or to be made, to residents of the Republic of Turkey in the Republic of Turkey. UBS Switzerland AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instrument/service may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 residents of the Republic of Turkey are allowed to purchase or sell the financial instruments traded in financial markets outside of the Republic of Turkey. Further to this, pursuant to article 9 of the Communiqué on Principles Regarding Investment Services, Activities and Ancillary Services No. III-37.1, investment services provided abroad to residents of the Republic of Turkey based on their own initiative are not restricted. **United Arab Emirates (UAE)**: UBS is not a financial institution licensed in the UAE by the Central Bank of the UAE nor by the Emirates' Securities and Commodities Authority and does not undertake banking activities in the UAE. UBS AG Dubai Branch is licensed by the DFSA in the DIFC. This document is provided for your information only and does not constitute financial advice. **United Kingdom**: This document is issued by UBS Wealth Management, a division of UBS AG which is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to retail clients of UBS Wealth Management. Ukraine: UBS is not registered and licensed as a bank/financial institution under Ukrainian legislation and does not provide banking and other financial services in Ukraine. UBS has not made, and will not make, any offer of the mentioned products to the public in Ukraine. No action has been taken to authorize an offer of the mentioned products to the public in Ukraine and the distribution of this document shall not constitute financial services for the purposes of the Law of Ukraine "On Financial Services and State Regulation of Financial Services Markets" dated 12 July 2001. Any offer of the mentioned products shall not constitute an investment advice, public offer, circulation, transfer, safekeeping, holding or custody of securities in the territory of Ukraine. Accordingly, nothing in this document or any other document, information or communication related to the mentioned products shall be interpreted as containing an offer, a public offer or invitation to offer or to a public offer, or solicitation of securities in the territory of Ukraine or investment advice under Ukrainian law. Electronic communication must not be considered as an offer to enter into an electronic agreement or other electronic instrument within the meaning of the Law of Ukraine "On Electronic Commerce" dated 3 September 2015. This document is strictly for private use by its holder and may not be passed on to third parties or otherwise publicly distributed. **USA**: Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliários Ltda., UBS Asesores México, S.A. de C.V., UBS SuMi TRUST Wealth Management Co., Ltd., UBS Wealth Management Israel Ltd. and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

© UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

